Abstract | Dendritic cells (DCs) are central in inducing immunity and in mediating immune tolerance in their role as professional antigen-presenting cells. In the absence of DCs, a fatal autoimmunity develops in animal models. Although the role of DCs has been investigated extensively in the pathogenesis of rheumatoid arthritis (RA), it remains unclear whether DCs initiate autoimmunity in this disease. Nevertheless, evidence points towards a significant role for DCs in disease maintenance and progression. Current biologic therapies target cytokine products of antigen-presenting cells, such as tumor necrosis factor, interleukin-1 and interleukin-6. Emerging therapies for RA exploit the tolerogenic capacity of DCs. 'Tolerogenic' DCs can be generated from myeloid precursors ex vivo, loaded with antigen, and manipulated to suppress autoimmune responses in vivo, through the induction of activation-induced cell death, anergy, and/or regulatory T cells. Cells that are primed by DCs, such as B cells, type 1 and type 17 T helper cells, and that have been implicated in certain models of autoimmunity, are also being considered as additional targets for immunebased therapy. Studies to validate these approaches to ameliorate autoimmunity will be necessary before their application in the clinic.
Background
Rheumatoid arthritis (RA) is an autoimmune disease marked by the infiltration of synovia and synovial compart ments with dendritic cells (DCs), monocytes, T cells, B cells, neutrophils and natural killer (NK) cells. 1 DCs have a central role in the induction of immunity (Box 1; Figure 1 ). In peripheral tissues, DCs exist as immature cells, and undergo differentiation after expo sure to pro inflammatory cytokines, immune complexes that contain autoantibodies, or pathogens and endo genous inflam matory factors (for example, heatshock proteins, high mobility group box1 protein) that are recog nized by Tolllike receptors (TLRs) expressed by DCs. Following migration to lymph nodes, mature DCs process acquired antigens onto major histo compatibility complex (MHC) molecules and present them to naive T cells. DCs also secrete cyto kines, directing naive T cells toward dif ferent types of T helper (T H ) cell: T H 1, T H 2 or T H 17 cells. 2 Furthermore, DCs promote the differen tiation and ma turation of antibodyproducing B cells ( Figure 1 ).
DCs are also important for maintaining intrathymic and peripheral tolerance, and their depletion in animal models is associated with the onset of fatal autoimmunetype disease. 3 Under steadystate conditions, im mature DCs recognize and phagocytose dying apoptotic cells during physiologic cell turnover, 4, 5 rendering DCs to lerogenic: they produce immunosuppressive cytokines and promote 'crosstolerance' . Responding T cells that are specific for the selfantigens contained within apoptotic cells are also rendered crosstolerant, becoming anergic, acquiring a regulatory immunosuppressive pheno type (T REG cells), or undergoing activationinduced cell death. 6 Tolerogenic DCs induce hyporesponsiveness even in memory CD4 + and CD8 + T cells. 7 Generally, this process does not result in DC maturation, but aberrations in this pathwayeither failed clearance of dead cells and/or exposure of DCs to maturation signals (for example, endo genous inflam matory factors and pathogens)-abrogates their tolerogenic capacity. 6, 7 In this article, we discuss the role of DCs in the patho genesis of RA in the context of other immune cells and soluble mediators, and evaluate emerging approaches to RA treatment that focus on DCs.
Preclinical data
The synovium of RA patients is characterized by the perivascular accumulation of immature and mature DC subsets, in close association with T cells and Bcell fol licles. 1, 8, 9 Synovial fluid from RA patients contains higher numbers of myeloid DCs (mDCs) 10 and plasmacytoid DCs (pDCs) (Box 1) compared to the blood, which signi fies a role for these antigenpresenting cells in disease perpetuation. 11 Results from in vitro studies suggest that DCs migrate into the joint in response to locally produced cytokines and chemokines, or differentiate locally from myeloid progenitors in response to growth factors present in synovial fluid. 12, 13 Competing interests N. Bhardwaj declares an association with the following organization: Rockefeller University. See the article online for full details of the relationship. The other authors declare no competing interests.
Antigen presentation and cytokine production DCs might contribute to ongoing inflammation through the presentation of autoantigens, as suggested by animal models of autoimmune arthritis, 14 or by producing pro inflammatory factors (Figure 1 ). DCs derived from the joint or from monocytes can present human cartilage glyco protein 39 and epitopes from synovial fluid con stituents, respectively, to antigenspecific T cells. 15, 16 Indeed, synovial DCs show evidence of activation in vivo in RA patients: upregulation of the expression of MHC molecules, co stimulatory molecules, RelB, 9 and receptor activator of nuclear factor κB (RANK) and its ligand (RANKL). 17 when stimulated ex vivo with immune complexes or TLR ago nists, synovial DCs respond with an increased production of proinflammatory cytokines, such as inter leukin (IL)1, IL6, and tumor necrosis factor (TNF). 1 DCs migrating into synovial fluid might undergo activation in response to locally produced cytokines or endogenous factors released from dying cells during inflammation. 18 Indirect contribution of DCs to RA pathogenesis DCs might also indirectly contribute to RA pathogenesis. Cytotoxic Tlymphocyteassociated protein 4 (CTLA4) is a negative regulator of Tcell activation that is also expressed on T REG cells. 19 CTLA4 expression on T REG cells suppresses DC activation by downregulating the co stimulatory m olecules CD80 and CD86, 19 but poly morphisms in the gene encoding CTLA4 that might possibly reflect either a lack of effector Tcell blockade or reduced T REG cell activity at the level of DCs are as sociated with RA. 20 The RA synovium is characterized by the forma tion of ectopic lymphoid organs resembling germinal centers. These centers contain plasma cells that express activationinduced cytidine deaminase and produce anti citrullinated protein antibodies (ACPAs). 21 ACPAs and rheumatoid factor are presumed to bind to Fc receptors on macrophages and DCs, inducing their activation and consequent production of proinflammatory cyto kines. 22 pDCs also accumulate in rheumatoid synovium and, through the production of type I interferon (IFN), might enhance autoantibody production. 23 Indeed, a subset of RA patients express a type I IFN signature that is associated with ACPA production. 24 DCs and t helper cell differentiation RA was initially considered to be driven by T H 1 cells. However, the identification of T H 17 cells and IL17 and IL23 within affected tissues and/or fluids of patients has implicated both T H 1 and T H 17 cells in RA patho genesis, 25, 26 particularly as the p40 subunit (common to both IL12 and IL23) and the IL23specific p19 subunit are essential for joint inflammation in the collageninduced arthritis mouse model. 27 DCs are required for the differentiation of T H 1 and T H 17 subsets from naive precursors ( Figure 1 ). T H 1 cells produce IFNγ, which ac tivates macrophages and enhances the production of IL1, IL6 and TNF. IL17 stimulates fibroblasts, endo thelial and epithelial cells to produce IL6 and IL8, recruits neutrophils and These cells and their products, such as tumor necrosis factor, interleukin-1 ■ and interleukin-6, localize in rheumatoid synovium
The proinflammatory products of DCs can be targeted to ameliorate RA ■ DCs can also be manipulated to induce tolerance in animal models; studies are ■ underway to test their tolerogenic activity in patients with RA monocytes, 28, 29 and, in animal models, induces osteo clastic bone resorption. 30, 31 Synovial tissue DCs express IL12 p70 and the IL23 subunit p19; these cytokines are essential for full differen tiation of T H 1 and T H 17 cells, respectively, providing a mechanism by which their pro duction is locally facilitated or perpetuated (Figure 1 ). 23 The presence of IL17 has been reported in the synovial fluid and membrane of RA patients, with its expression predicting radiologic disease progression; 30, 32 however, other reports suggest that this cytokine and T H 17 cells are not abundant in rheumatoid synovial fluid. 33 Furthermore, va riants of IL12B (which encodes the p40 subunit of IL12) 
and IL23R, which have previously been associated with inflammatory diseases, do not seem to confer a signifi cantly increased risk of developing RA. 34 Brentano et al. 35 have observed abundant expression of the p19 subunit, but not the p40 subunit, of IL23 in RA synovial lining, in dicating that bioactive IL23 is not produced by synovio cytes. Furthermore, levels of bioactive IL23 did not differ signifi cantly between RA and osteo arthritis syno vial fluid. 35 Transgenic expression of p19 in mice leads to systemic inflammation, 36 so perhaps it contri butes to RA through p40independent mechanisms. 35 In summary, further verification for a role of T H 17 cells and related cytokines in RA pathogenesis is required.
Inducing DC tolerance
The development of animal models in which DCs are selectively depleted should enable the specific role of these cells in the pathogenesis of autoimmune arthri tis to be addressed. 3, 37 Nevertheless, DCs can also be exploited to induce tolerance in vivo. In animal models, immunomodulation of immature DCs using immuno suppressive cytokines, genetic engineering, proteins and drugs confers tolerance by favoring T H 2mediated immune responses over T H 1mediated proinflammatory responses, or by inducing IL10producing T REG cells, anergy or activationinduced cell death. 38 Human immature DCs can be rendered tolerogenic in vitro by preexposure to autologous apoptotic cells (which express selfantigens), skewing Tcell priming and preventing the activation of memory T cells. 6 Ligation of individual receptors on human DCs that recognize apop totic cells (such as CR3 and CR4) in hibits IL12 produc tion, generates transforming growth factor β (TGFβ) and specifically causes Tcell anergy and activationinduced cell death. 7 DC maturation can also be abrogated in situ using antibodies to Ctype lectin receptors. 39 when com plexed to antigens, antibodies to DEC205 induce T REG cells in animal models. 40 Similarly, Ctype lectin recep tors, such as the DC immuno receptor, negatively regulate the function of DCs. 41 A comparison of these different approaches to inducing tolero genic DCs is warranted to identify those most efficacious in inducing tolerance.
Future clinical development
Patients who do not respond to DMARDs such as metho trexate require additional treatment with biologic agents, such as those that target TNF, IL1 (produced by joint constituents, including DCs), B cells or costimulatory molecules on DCs. AntiTNF therapies ameliorate clini cal symptoms and also reduce the number of peripherally activated mDCs and pDCs in vivo; in vitro, the treatment diminishes DC maturation and their capability of pro ducing proinflammatory cytokines and chemokines. 13, 42 These observations reinforce the strategy of targeting mediators of inflammation and bone resorption, par ticularly at the level of the DC (Supplementary Table 1 online). Below, we review emerging therapies that focus on DCs and related targets to treat RA.
tolerogenic DCs
The administration of tolerogenic DCs, or even T REG cells, might be treatment options for patients with recal citrant disease. In the first human study to test the effects of tolerogenic DCs, we showed that injection of imma ture DCs pulsed with influenza matrix peptide resulted in the transient induction of antigenspecific, IL10 producing, CD8 + T REG cells that blocked IFNγ produc tion and cytolytic function by effector CD8 + T cells. 43 The effect of injecting autologous, monocytederived DCs pulsed with a mixture of four citrullinated peptide antigens derived from vimentin, fibrinogen α chain, fibrinogen β chain and collagen type II into patients with RA who express RAassociated DRB1 alleles 44 and are ACPApositive is currently being studied (R. Thomas, personal communica tion). The DCs are pretreated with BAY 117082, an inhibitor of RelB nuclear translocation, which renders them tolerogenic, and then subsequently pulsed with the peptides. 45 If determined to be safe, it might be possible to advance tolerogenic DC therapy by simulta neously blocking costimulation using, for example, abatacept, which maintains DCs in their imma ture, tolero genic form; this strategy has shown proven sy nergistic effects in animal models of transplantation. 46 Inhibitors of co-stimulation T REG cells employ several mechanisms to maintain selftol erance: production of TGFβ and IL10, inhibition of cell metabolism and blockade of DC function via CTLA4, and sequestration from effector T cells. 19, 47 Abatacept, a CTLA4-Ig fusion protein that modulates Tcell co stimulation, has proven efficacious in RA patients who are resistant to DMARDs and antiTNF therapy. The fusion protein might also enhance the expression in mDCs and pDCs of indoleamine 2,3 dioxygenase (IDo), an enzyme that metabolizes tryptophan to kynurenine and induces the di fferentiation of T REG cells from naive T cells. [48] [49] [50] Inflammatory cytokines
IL-6
IL6 is a prototypic inflammatory cytokine found in RA synovial fluid. 51 Tocilizumab, an antibody that binds the IL6 receptor, has proven efficacious in the treatment of RA in combination with DMARDs, and is currently in phase III trials (Supplementary Table 1 online) . 52 
IL-23
IL23 is required for the maturation of T H 17 cells (Figure 1) . Neutralizing antibodies to p40-ustekinumab and ABT874-have shown promise against psoriasis and inflammatory bowel disease, but await testing in RA patients. 53 Targeting the p19 subunit of IL23 might provide a more selective way of blocking T H 17 differen tiation without affecting T H 1 cells, as T H 1 cells are also required for immunity against pathogens.
IL-17
Clinical trials are underway to test agents that target IL17 as well as IL22, another cytokine produced by T H 17 cells. Unlike T H 1 cells, T H 17 cells are resistant to suppression by T REG cells in animal models of auto immunity. 54 How ever, T H 17 cells directly stimulate the production of IL6 and TNF at sites of inflammation; these cytokines abrogate T REG cell development. Current antiIL1 and antiIL6 therapeutics might also ameliorate inflammation by inhibiting T H 17 cell differentiation.
Inhibitors of osteoclastogenesis RANKL is expressed by DCs, T cells (for example, T H 17 cells) and fibroblastlike cells; its interaction with RANK on osteoclast progenitor cells induces osteoclasto genesis. Denosumab, an antibody against RANKL, has been shown to retard radiologic progression in RA. 55 
Small molecule inhibitors
The intracellular kinases Janus kinase 3 (JAK3) and spleen tyrosine kinase (Syk) are involved in signaling through the common γ chain of cytokine receptors and/ or receptors that have immunoreceptor tyrosinebased activation motifs (such as the Fcγ receptor). As rheuma toid synovial tissue DCs express JAK3, inhibitors of JAK3 could conceivably block DC activation. 53 JAK3 and Syk inhibitors in RA have shown encouraging results in phase II trials. 53 Mutations in STAT4, which encodes a transcription factor that transduces signals from IL12, IL23 and type 1 IFN in T cells and monocytes, and STAT3, which encodes a transcription factor critical for T H 17 cell differentiation, have been linked to RA. 20, 26 These transcription factors, in addition to those govern ing T H 17 differentiation (such as retinoic acidrelated orphan receptor [RoRγt] and aryl hydrocarbon recep tors), are potential attractive targets for RA therapy. A caveat of inhibiting transcription factors, however, is the potential for adverse effects as the pathways are common across multiple cell types.
Outlook
DCs have the potential to treat autoimmunity by virtue of their natural ability to induce tolerance in vivo. The identifica tion of relevant antigens in RA and optimal approaches to generating tolerogenic DCs will be required to maximize their immunomodulatory activity. Studies linking genetic alterations with RA make it conceivable that therapy might be further tailored to gain maximum benefit. Approaches to targeting inhibitory receptors on DCs (for example, CR3 and DEC205) with antigen fused to antibodies are another option for inducing DC toler ance and preventing maturation. It is possible that other DC subsets, such as pDCs, could be used to induce toler ance: when activated via TLRs or following engagement of CD80 or CD86 with CTLA4, pDCs express IDo and induce T REG cells. 49, 56 Induction of IDo in animal models of arthritis controls the accumulation of pathogenic T cells at the site of inflammation, 57, 58 and IDoexpressing DCs can reverse arthritis. 58 The combination of established therapies, along with active immuno modulation through the use of DCbased thera pies, might further improve our ability to ameliorate auto immunity in RA.
Review criteria
Our search efforts included the PubMed database and Cochrane Library using the term "rheumatoid arthritis" in association with specific terms, including "dendritic cells and autoimmunity", "dendritic cells and regulatory T cells", and "tolerogenic dendritic cells". We reviewed all types of article, including original papers, Review articles and case reports published between June 1999 and June 2009. Efforts were made to refer to primary papers whenever possible, or to comprehensive Reviews. In addition, we searched clinicaltrials.gov to identify ongoing clinical trials using dendritic cells to treat autoimmune diseases and current therapies in clinical trials for rheumatoid arthritis.
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